The group's principal activity is to innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases. The group's product include lysosomal storage diseases, Glycosylation Independent Lysosomal Targeting and lysosomal enzyme. The group operates from the United States.
